Premium
NDUFS1 as a prognostic marker in lung cancer: a clinicopathological analysis of 106 cases of non‐small cell lung cancer
Author(s) -
Su Chia Yi,
Hsiao Michael
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.58.7
Subject(s) - immunostaining , lung cancer , adenocarcinoma , immunohistochemistry , stage (stratigraphy) , cancer , medicine , lung , oncology , pathology , cancer research , biology , paleontology
In spite of therapy available nowadays, some lung cancer patients diagnosed with early stage tend to have more aggressive prognosis. In recent years considerable concern has arisen over identifying prognostic markers. Little has been known about the relation between NADH dehydrogenase (ubiquinone) Fe‐S protein 1 (NDUFS1), a marker involved in catalysis and cell metabolism, and lung cancer. To investigate the clinicopathological characters, immunohistochemical staining for NDUFS1 was performed on 106 non‐small cell lung cancer (NSCLC) patients. Immunoreactivity was seen positive in 80 tumors and higher than corresponding non‐tumor tissues (p<0.001). In NSCLC and adenocarcinoma, positive NDUFS1 immunoreactivity was associated with lower T stage (p=0.007 and p=0.008, respectively) and longer overall survival (p=0.028 and p=0.05, respectively). It is worth pointing out that in early stage adenocarcinoma, positive NDUFS1 immunostaining had a trend toward being correlated with longer overall survival (p=0.091). NDUFS1 was further identified to interact with c‐MYC through bioinformatics database analysis. Further experimental results showed that NDUFS1 regulated c‐MYC‐associated pathway to involve tumorigenicity in vitro and in vivo. In summary, we identified a novel marker NDUFS1 which plays an important role in tumor metabolism and correlates with favorable prognosis of NSCLC.